SlideShare a Scribd company logo
1 of 8
Download to read offline
Name: Siti Nurul Afiqah binti Johari
ID No.: 10-6-95
VENOUS THROMBOEMBOLISM IN PREGNANCY
Women are at an increased risk of both venous and arterial thromboembolism during
pregnancy. Compared to women who are not pregnant, the risk of arterial thromboembolism
(strokes and heart attacks) is increased 3- to 4-fold and the risk of venous thromboembolism
(VTE) is increased 4- to 5-fold. Postpartum, the risk is even higher (20-fold). The overall
prevalence of thromboembolic events during pregnancy is approximately 2 per 1000
deliveries. Approximately 20% of these events are arterial, and the other 80% are venous.
VTE accounts for 1.1 deaths per 100 000 deliveries, or 10% of all maternal deaths.
Approximately 80% of venous thromboembolic events during pregnancy are deep vein
thrombosis (DVT) and 20% are pulmonary emboli. Approximately one third of pregnancy-
related DVT and half of pregnancy-related pulmonary emboli occur after delivery. When
DVT occurs during pregnancy, it is more likely to be proximal, massive,and in the left lower
extremity. Distal thrombosis are as likely to occur on the right as on the left, but proximal
thrombosis occurring under the influence of estrogen are more likely to be on the left. This
left-sided predominance is thought to be attributable to a relative stenosis of the left common
iliac vein where it lies between the lumbar vertebral body and the right common iliac artery,
but the true mechanism is unknown. Pelvic vein thrombosis, which account for less than 1%
of all cases of DVT, are rare outside of pregnancy or pelvic surgery yet account for
approximately 10% of DVT during pregnancy and the postpartum period.
Pregnant women are probably at an increased risk for VTE as a result of hormonally induced
decreased venous capacitance and decreased venous outflow, possibly as a result of
mechanical obstruction by the uterus, and questionably as a result of decreased mobility.
These factors, along with vascular injury, are important, especially during the postpartum
period, but the risk of VTE is as high during the first trimester as it is during the second and
third trimesters. Therefore, the risk of VTE increases before many of the anatomic changes of
pregnancy take place, suggesting that; overall, the most important reason for the increased
risk of VTE during pregnancy is hypercoagulability.
Normal pregnancy is accompanied by increased concentrations of factors VII, VIII, X, and
von Willebrand factor and by pronounced increases in fibrinogen. Factors II, V, and IX are
relatively unchanged. Free protein S, the active, unbound form, is decreased during pregnancy
secondary to increased levels of its binding protein, the complement component C4b.
Plasminogen activator inhibitor type 1 (PAI-1) levels increase 5-fold. Levels of PAI-2,
produced by the placenta, increase dramatically during the third trimester. Markers of
thrombin generation such as prothrombin F1+2 and thrombin-antithrombin (TAT) complexes
are increased. These changes, which may not completely return to baseline until more than 8
weeks postpartum, begin with conception. So does the risk of thrombosis.
The hypercoagulability of pregnancy has likely evolved to protect women from hemorrhage
at the time of miscarriage or childbirth. Indeed, in the developing world, the leading cause of
maternal death is still hemorrhage, but in Western Europe and the United States, where
hemorrhage is successfully treated or prevented, the leading cause of maternal death is
thromboembolic disease.
Risk Factors for Thrombosis in Pregnancy
There are a number of known risk factors, some hereditary and others acquired. In 80% of
patients, at least one risk factor can be identified. Notably, the antenatalperiod is known to be
a weak risk factor and the postpartum period a moderate risk factor.
Often more than one risk factor is present and these should be actively identified when
assessing the patient for VTE during and post-pregnancy.
Inherited factors
 Factor V Leiden mutation (most common).
 Prothrombin gene G20210A mutation.
 Antithrombin III deficiency.
 Protein C deficiency.
 Protein S deficiency.
 Hyperhomocysteinaemia.
 Dysfibrinogenaemia.
 Disorders of plasminogen and plasminogen activation.
 Strong family history.
Acquired factors
 Obesity - body mass index (BMI) ≥30 kg/m2
.
 Immobilization (>4 days of bed rest).
 Previous thrombotic event.
 Smoking.
 Trauma.
 Inflammatory disorders such as inflammatory bowel disease.
 Cancer.
 Estrogen therapy (including contraception and hormone replacement therapy).
 Sepsis, including urinary tract infections.
 Gross varicose veins.
 Antiphospholipid syndrome.
 Nephrotic syndrome.
 Paroxysmal nocturnal haemoglobinuria.
 Cerebrovascular event.
 Polycythaemia vera.
 Sickle cell disease.
 Lupus.
 Anemia.
 Diabetes.
 Hypertension.
 Long-haul travel of ≥4 hours.
Factors specific to pregnancy and delivery complications
 Venous stasis.
 Maternal age of ≥35 years.
 Multiparity.
 Gestation <36 weeks.
 Instrument-assisted or caesarean delivery.
 Haemorrhage (antepartum and postpartum)
 Pre-eclampsia.
 Prolonged labour.
 Hyperemesis.
 Postpartum infection.
Clinical Presentation
Presentation is similar to non-pregnant patients with DVT or PE.
 DVT: leg pain and discomfort (the left is more commonly affected), swelling,
tenderness, edema, increased temperature and a raised white cell count. There may
also be abdominal pain. The difficulty is that some of these symptoms may be found
in normal pregnancies. The patient may also be asymptomatic with a retrospective
diagnosis being made following a PE.
 PE: dyspnea, pleuritic chest pain, hemoptysis, faintness, collapse. The patient may
have focal signs in the chest, tachypnea, a raised jugular venous pressure (JVP) and
there may be ECG changes (S1Q3T3). Arterial blood gases with the patient sitting
down may show respiratory alkalosis and hypoxemia. There may also be symptoms
or signs of a DVT.
Differential Diagnosis
 DVT: swelling and lower leg discomfort are not unusual in a normal pregnancy.
Other possibilities include muscle strain, a ruptured Baker’s cyst, cellulitis,
superficial thrombophlebitis, ruptured plantaris tendon and trauma.
 PE: potentially extensive but specifically rule out chest infection and an intra-
abdominal bleed (look for abdominal signs, shoulder tip pain from diaphragmatic
irritation and a low JVP).
Diagnostic Approach of VTE
The two most common initial symptoms, present in more than 80% of women with
pregnancy-related DVT, are pain and swelling in an extremity. When signs or symptoms
suggest new onset DVT, the recommended initial diagnostic test is compression
ultrasonography of the proximal veins. When results are equivocal or an iliac vein thrombosis
is suspected, magnetic resonance venography (MRV) may be used.
The diagnosis of new onset pulmonary embolism (PE) is similar to that in the non-pregnant
individual. Ventilation/perfusion (V/Q) scanning gives relatively low radiation exposure to
the fetus. With an indeterminate study in a woman without a DVT, a confirmatory test, such
as angiography or spiral computed tomography (spiral CT), is necessary to prevent the
woman from unnecessary exposure to anticoagulation during the rest of her pregnancy, at
delivery, or in future pregnancies.
Management of VTE
Massive life-threatening PE:
 Collapsed, shocked patients need to be managed by an experienced multidisciplinary
team involving senior obstetricians, physicians and radiologists.
 An urgent portable echocardiogram or CTPA within one hour of presentation should
be arranged.
 If massive PE is confirmed or, in extreme circumstances prior to confirmation,
immediate thrombolysis should be considered.
 Intravenous unfractionated heparin is the preferred treatment.
General points
 In a woman with a past history of VTE or with a known inherited thrombophilia, it is
best to refer her prior to a planned pregnancy for optimum prophylaxis throughout the
pregnancy. Refer all women who are on warfarin, as this will have to be stopped or
replaced by heparin before the seventh week of conception, depending on her risk of
VTE.
 Medical anticoagulation is the treatment of choice for acute VTE. Subsequently,
surgical interventions may be considered: patients suffering from recurrent PEs
despite adequate anticoagulation (or where there is an absolute contra-indication to
anticoagulation) may benefit from placement of a temporary caval filter and, in those
cases where there is limb or life-threatening embolus, a surgical embolectomy or
thrombus fragmentation may be attempted.
 Anticoagulation is by far the most common treatment option. Heparin is the most
frequently used drug, being non-toxic to the fetus (it does not cross the placental
barrier). However, its main disadvantages are that it has to be parentally administered
and, in the long-term, may give rise to heparin-induced osteoporosis and
thrombocytopenia. In some patients, it can also provoke a painful, localized allergic
reaction on administration. Warfarin is the other treatment option in the postnatal
patient but it must be avoided antenatally, as it is teratogenic and can also cause
placental abruption and fetal/neonatal hemorrhage.
 In clinically suspected DVT or PE, treatment with unfractionated heparin or LMWH
should be given until the diagnosis is excluded by objective testing, unless treatment
is strongly contraindicated.
Initiating treatment
There are severaldifferent types of heparin to choose from:
 LMWH: this is the drug of choice. It has been shown to be more effective than
unfractionated heparin with lower mortality and fewer hemorrhagic complications in
the initial treatment of DVT in non-pregnant subjects. LMWHs are as effective as
unfractionated heparin for treatment of PE. The exact dose will depend on the
manufacturer's recommendations but this is based on the patient's early pregnancy
weight and should be administered subcutaneously twice daily. There should be clear
local guidelines for the dosage of LMWH to be used.
 Intravenous unfractionated heparin: this is an extensively used drug in the acute
management of VTE, particularly massive PE with cardiovascular compromise. It is
initiated with a loading dose of 5,000 international units (IU) followed by a
continuous infusion of 1,000-2,000 IU/hour depending on activated partial
thromboplastin time (aPTT) measurements (daily - at least), the first of which is taken
six hours after the loading dose. Thus, there is the benefit of accurate drug
administration but it has been demonstrated that there are a number of difficulties
with accurate aPTT measurement (when the sample is taken and in the laboratory),
particularly late in pregnancy when interpretation of the results can be problematic.
Prolonged use in pregnancy may give rise to the problems described above.
 Subcutaneous unfractionated heparin: this has been shown to be as effective as the
intravenous form. It is administered as a 5,000 IU bolus and subsequent 15,000-
20,000 IU doses at 12-hourly intervals. The aPTT needs to be checked and is best
done midway between the 12-hourly doses, once every 24 hours. A target of 1.5-2.5
times the control should be aimed for.
Additionally, the leg should be elevated and a graduated elastic compression stocking applied
to reduce oedema. Mobilisation with graduated elastic compression stockings should be
encouraged.
Maintenance therapy
Pregnancy
Heparins are the maintenance treatment of choice. Dose-adjusted subcutaneous,
unfractionated heparin or subcutaneous LMWH are effective alternatives to oral
anticoagulants in maintenance treatment of VTE.
 Subcutaneous LMWH appears to have advantages over aPTT-monitored
unfractionated heparin in the maintenance treatment of VTE in pregnancy. The
simplified therapeutic regimen for LMWH tends to be more convenient for patients,
minimising blood tests (routine platelet counts are not required and levels of anti-Xa
will only need to be monitored where there are extremes of weight: <50 kg or >90 kg)
and allowing outpatient treatment. Women should be taught to self-inject and can
then be managed as outpatients until delivery.
 If unfractionated heparin is used, monitor the platelet count at least every other day
for the first 14 days or until treatment is stopped (whichever comes first).
Seek specialist advice if the patient develops heparin-induced thrombocytopenia or a heparin
allergy and requires continuing anticoagulant therapy. She should be managed with the
heparinoid, danaparoid sodium or fondaparinux, under specialist supervision.
Labour
When the patient thinks she is going into labour, she should stop injecting and get in touch
with the delivery ward staff that will manage the anticoagulation throughout labour and
immediately post-delivery. Alternatively, planned elective induction of labour or caesarean
section at least 12 hours after prophylactic-dose LMWH or 24 hours after therapeutic-dose
LMWH can be considered. As these patients are at high risk of hemorrhage, they will be
managed with intravenous unfractionated heparin throughout this time. Regional anaesthetic
or analgesic techniques should not be undertaken until at least 24 hours after the last dose of
therapeutic LMWH.
Postpartum
Depending on the patient's individual circumstances, she may be managed with ongoing
heparin treatment or warfarin postpartum. If she opts for warfarin, this needs to be avoided
until at least day three postpartum with an INR check at day two of warfarin treatment: aim
for an INR between 2 and 3. Continue heparin treatment until there have been two successive
readings of an INR >2. Although these drugs are detectable in breast milk, all are safe for use
during breast-feeding because warfarin metabolites are inactive and heparin is not absorbed
through the gastrointestinal tract.
Postnatal review for women who develop VTE during pregnancy or the puerperium should,
whenever possible, be at an obstetric medicine clinic or a joint obstetric hematology clinic.
Stopping treatment
In theory, therapy should be continued for six months as would be the case for non-pregnant
patients. However, the postpartum state is a period of physiological fluctuation of coagulation
factors. Therefore, current advice is to continue therapy for at least 6-12 weeks postpartum or
until at least three months of therapy have been completed. At that point, the patient should be
assessed for the presence of ongoing risk factors for a VTE prior to making the decision to
stop anticoagulation therapy.
Complications
Thrombophilia and placental vascular complications
 Fetal loss: although the figures are likely to be small (there are not many studies),
there is thought to be a doubling of risk of fetal loss in women with genetic
thrombophilia.
 Intrauterine growth restriction: a specific association between this and
thrombophilia has not been identified but chronic abruption and extensive placental
infraction have been noted to occur more frequently in these patients.
 HELLP syndrome: Hemolysis, Elevated Liver enzymes, Low Platelet count - this
may be associated with certain forms of thrombophilia.
Post-thrombotic syndrome
Up to 60% of patients who have experienced a DVT go on to have post-thrombotic syndrome
up to 12 months following the acute event. This arises from damage to the lumen of the vein
following the presence of a thrombus. Subsequently, patients manifest symptoms and signs
akin to those of varicose veins: aching, swollen legs, pruritus, dermatitis and
hyperpigmentation of the affected area. Ulceration and cellulitis may complicate the picture.
Compression stockings worn on the affected leg for at least two years have been
recommended after the acute event to reduce the risk of developing post-thrombotic
syndrome. However, a recent large randomized trial found no evidence to support this. PE is
the other complication of DVTs and is discussed above.
Other complications
Prolonged unfractionated heparin use during pregnancy may result in osteoporosis and
fractures.
Prevention: prophylaxis
Guidance from the Royal College of Obstetricians and Gynecologists’ suggests:
Antenatally
 Regardless of their VTE risk, dehydration and immobilization of the patient should
be avoided throughout pregnancy.
 Women at high risk of VTE in pregnancy should be offered pre-pregnancy
counseling and a prospective management plan for thromboprophylaxis in pregnancy.
Those who become pregnant before receiving such counseling should be referred to a
nominated expert early in pregnancy.
 All women with previous VTE should receive postpartum prophylaxis, as this is the
time of highest risk.
 In addition, women whose original VTE was unprovoked, idiopathic or related to
estrogen, or who have other risk factors, a family history of VTE in a first-
degree relative or a documented thrombophilia require LMWH antenatally and for
six weeks postpartum.
 Women with recurrent VTE may already be on warfarin. They should be advised to
stop warfarin and change to LMWH as soon as pregnancy is confirmed, ideally
within two weeks of the missed period and before the sixth week of pregnancy.
Women not on warfarin should be advised to start LMWH as soon as they have a
positive pregnancy test.
 Women with asymptomatic inherited or acquired thrombophilia only, may be
managed with close surveillance antenatally and be considered for LMWH for at least
seven days postpartum. Exceptions are women with antithrombin deficiency, those
with more than one thrombophilic defect (including homozygosity for factor V
Leiden) or those with additional risk factors where antenatal prophylaxis should be
considered.
Intrapartum
Women taking LMWH should be advised that, if they bleed vaginally or contractions begin,
they should not inject any further doses. They should be assessed in hospital and further doses
be prescribed by medical staff.
Postpartum
 All women with obesity (BMI greater than 40 kg/m2
) should be considered for
prophylactic LMWH for seven days after delivery. Other postnatal risks include
prolonged labour, immobility, infection, hemorrhage and blood transfusion.
 All women who have had an emergency Caesarean section should be considered for
LMWH for seven days after delivery. All women who have had an elective caesarean
section who have one or more additional risk factors should be considered for
LMWH for seven days after delivery.
In addition, properly applied graduated compression stockings are recommended for women
travelling long-distance for more than four hours, women who are still outpatients but have
prior VTE (usually combined with LMWH), women who are hospitalized and have a contra-
indication to LMWH and those who are hospitalized post-caesarean section (combined with
LMWH) and considered to be at particularly high risk of VTE.
References:
1. http://www.aafp.org/afp/2008/0615/p1709.html
2. http://atvb.ahajournals.org/content/29/3/326.full
3. http://patient.info/doctor/venous-thromboembolism-in-pregnancy#ref-3

More Related Content

What's hot

THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERYTHROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERYAboubakr Elnashar
 
Prevention of Venous Thrombo-Embolism
Prevention of Venous Thrombo-EmbolismPrevention of Venous Thrombo-Embolism
Prevention of Venous Thrombo-Embolismlimgengyan
 
04 yoo kuen chan
04 yoo kuen chan04 yoo kuen chan
04 yoo kuen chanDuy Quang
 
Life after menopause
Life after menopauseLife after menopause
Life after menopauseEddie Lim
 
Hypertensive Disorders in Pregnancy Update April 2019
Hypertensive Disorders in Pregnancy Update April 2019Hypertensive Disorders in Pregnancy Update April 2019
Hypertensive Disorders in Pregnancy Update April 2019Kervindran Mohanasundaram
 
Venous Thromboembolism and Pregnancy
Venous Thromboembolism and PregnancyVenous Thromboembolism and Pregnancy
Venous Thromboembolism and PregnancyRavulJindal
 
Postnatal thromboprophylaxis RCOG Recommendations
Postnatal thromboprophylaxis RCOG RecommendationsPostnatal thromboprophylaxis RCOG Recommendations
Postnatal thromboprophylaxis RCOG RecommendationsAsha Reddy
 
Thromboprophylaxis
ThromboprophylaxisThromboprophylaxis
ThromboprophylaxisAasma Hanif
 
Thrombophilia & Thromboembolism in Pregnancy & Puerperium
Thrombophilia & Thromboembolism in Pregnancy & PuerperiumThrombophilia & Thromboembolism in Pregnancy & Puerperium
Thrombophilia & Thromboembolism in Pregnancy & PuerperiumJagannath Mishra
 
Management of Postpartum Hypertesion
Management of Postpartum HypertesionManagement of Postpartum Hypertesion
Management of Postpartum HypertesionEddie Lim
 
Care in Pregnancies Subsequent to Stillbirth or Perinatal Death
Care in Pregnancies Subsequent to Stillbirth or Perinatal DeathCare in Pregnancies Subsequent to Stillbirth or Perinatal Death
Care in Pregnancies Subsequent to Stillbirth or Perinatal DeathKervindran Mohanasundaram
 
Renal transplantation and pregnancy
Renal transplantation and pregnancyRenal transplantation and pregnancy
Renal transplantation and pregnancySalwa Ibrahim
 
COMPLICATIONS OF HYPERTENSIVE DISORDERS OF PREGNANCY BY DR SHASHWAT JANI
COMPLICATIONS OF HYPERTENSIVE DISORDERS OF PREGNANCY BY DR SHASHWAT JANICOMPLICATIONS OF HYPERTENSIVE DISORDERS OF PREGNANCY BY DR SHASHWAT JANI
COMPLICATIONS OF HYPERTENSIVE DISORDERS OF PREGNANCY BY DR SHASHWAT JANIDR SHASHWAT JANI
 

What's hot (20)

Venous thromboembolism of pregnancy
Venous thromboembolism of pregnancyVenous thromboembolism of pregnancy
Venous thromboembolism of pregnancy
 
Pulmonary Embolism in Geriatrics
Pulmonary Embolism in GeriatricsPulmonary Embolism in Geriatrics
Pulmonary Embolism in Geriatrics
 
Prepregnancy Care Update April 2019
Prepregnancy Care Update April 2019Prepregnancy Care Update April 2019
Prepregnancy Care Update April 2019
 
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERYTHROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
 
Prevention of Venous Thrombo-Embolism
Prevention of Venous Thrombo-EmbolismPrevention of Venous Thrombo-Embolism
Prevention of Venous Thrombo-Embolism
 
Thrombo
ThromboThrombo
Thrombo
 
04 yoo kuen chan
04 yoo kuen chan04 yoo kuen chan
04 yoo kuen chan
 
Life after menopause
Life after menopauseLife after menopause
Life after menopause
 
Hypertensive Disorders in Pregnancy Update April 2019
Hypertensive Disorders in Pregnancy Update April 2019Hypertensive Disorders in Pregnancy Update April 2019
Hypertensive Disorders in Pregnancy Update April 2019
 
Venous Thromboembolism and Pregnancy
Venous Thromboembolism and PregnancyVenous Thromboembolism and Pregnancy
Venous Thromboembolism and Pregnancy
 
Postnatal thromboprophylaxis RCOG Recommendations
Postnatal thromboprophylaxis RCOG RecommendationsPostnatal thromboprophylaxis RCOG Recommendations
Postnatal thromboprophylaxis RCOG Recommendations
 
Thromboprophylaxis
ThromboprophylaxisThromboprophylaxis
Thromboprophylaxis
 
Anesthesia During Pregnancy
Anesthesia During PregnancyAnesthesia During Pregnancy
Anesthesia During Pregnancy
 
Thrombophilia & Thromboembolism in Pregnancy & Puerperium
Thrombophilia & Thromboembolism in Pregnancy & PuerperiumThrombophilia & Thromboembolism in Pregnancy & Puerperium
Thrombophilia & Thromboembolism in Pregnancy & Puerperium
 
Management of Postpartum Hypertesion
Management of Postpartum HypertesionManagement of Postpartum Hypertesion
Management of Postpartum Hypertesion
 
Care in Pregnancies Subsequent to Stillbirth or Perinatal Death
Care in Pregnancies Subsequent to Stillbirth or Perinatal DeathCare in Pregnancies Subsequent to Stillbirth or Perinatal Death
Care in Pregnancies Subsequent to Stillbirth or Perinatal Death
 
Snigdha
Snigdha Snigdha
Snigdha
 
Renal transplantation and pregnancy
Renal transplantation and pregnancyRenal transplantation and pregnancy
Renal transplantation and pregnancy
 
COMPLICATIONS OF HYPERTENSIVE DISORDERS OF PREGNANCY BY DR SHASHWAT JANI
COMPLICATIONS OF HYPERTENSIVE DISORDERS OF PREGNANCY BY DR SHASHWAT JANICOMPLICATIONS OF HYPERTENSIVE DISORDERS OF PREGNANCY BY DR SHASHWAT JANI
COMPLICATIONS OF HYPERTENSIVE DISORDERS OF PREGNANCY BY DR SHASHWAT JANI
 
High risk pregnancy4
High risk pregnancy4High risk pregnancy4
High risk pregnancy4
 

Viewers also liked

Satellite manufacturing~upstream & downstream analysis
Satellite manufacturing~upstream & downstream analysisSatellite manufacturing~upstream & downstream analysis
Satellite manufacturing~upstream & downstream analysisTVS Logistics Services Ltd
 
Projeto PrioritáRio[1]
Projeto PrioritáRio[1]Projeto PrioritáRio[1]
Projeto PrioritáRio[1]gildoosmar
 
Protocolo TCP/IP
Protocolo TCP/IPProtocolo TCP/IP
Protocolo TCP/IPSubiluntar
 
A sample Control Design Project
A sample Control Design ProjectA sample Control Design Project
A sample Control Design Projectsubarna Giri
 
writing ethnographic field notes
writing ethnographic field noteswriting ethnographic field notes
writing ethnographic field notesNikki Usher
 
Siem Reap (Camboya)
Siem Reap (Camboya)Siem Reap (Camboya)
Siem Reap (Camboya)F. Ovies
 
Pure Progression: Optimising Email - November 2016
Pure Progression: Optimising Email - November 2016Pure Progression: Optimising Email - November 2016
Pure Progression: Optimising Email - November 2016Pure360
 
Power musica
Power  musicaPower  musica
Power musicantpalau
 
Silverman qualitative research - chapter 2 - ethnography
Silverman   qualitative research - chapter 2 - ethnographySilverman   qualitative research - chapter 2 - ethnography
Silverman qualitative research - chapter 2 - ethnographyNikki Usher
 
Sihanoukville
Sihanoukville Sihanoukville
Sihanoukville F. Ovies
 
2016 Social Media Best Practices for ITB
2016 Social Media Best Practices for ITB2016 Social Media Best Practices for ITB
2016 Social Media Best Practices for ITBKen Herron
 
Músculos del pie, fascia y aponeurosis plantar
Músculos del pie, fascia y aponeurosis plantarMúsculos del pie, fascia y aponeurosis plantar
Músculos del pie, fascia y aponeurosis plantarGRUPOAUAT
 
Pilpilén
PilpilénPilpilén
PilpilénMuseal3
 
Newer Oral Anticoagulants or warfarin in DVT/PE
Newer Oral Anticoagulants or warfarin in DVT/PENewer Oral Anticoagulants or warfarin in DVT/PE
Newer Oral Anticoagulants or warfarin in DVT/PESatyam Rajvanshi
 

Viewers also liked (19)

Satellite manufacturing~upstream & downstream analysis
Satellite manufacturing~upstream & downstream analysisSatellite manufacturing~upstream & downstream analysis
Satellite manufacturing~upstream & downstream analysis
 
Projeto PrioritáRio[1]
Projeto PrioritáRio[1]Projeto PrioritáRio[1]
Projeto PrioritáRio[1]
 
Behaviorism vocab
Behaviorism vocabBehaviorism vocab
Behaviorism vocab
 
Protocolo TCP/IP
Protocolo TCP/IPProtocolo TCP/IP
Protocolo TCP/IP
 
A sample Control Design Project
A sample Control Design ProjectA sample Control Design Project
A sample Control Design Project
 
writing ethnographic field notes
writing ethnographic field noteswriting ethnographic field notes
writing ethnographic field notes
 
20 nazzicari
20 nazzicari20 nazzicari
20 nazzicari
 
BIO-DATA of Quazi Salahuddin
BIO-DATA of Quazi SalahuddinBIO-DATA of Quazi Salahuddin
BIO-DATA of Quazi Salahuddin
 
Siem Reap (Camboya)
Siem Reap (Camboya)Siem Reap (Camboya)
Siem Reap (Camboya)
 
Pure Progression: Optimising Email - November 2016
Pure Progression: Optimising Email - November 2016Pure Progression: Optimising Email - November 2016
Pure Progression: Optimising Email - November 2016
 
Power musica
Power  musicaPower  musica
Power musica
 
Silverman qualitative research - chapter 2 - ethnography
Silverman   qualitative research - chapter 2 - ethnographySilverman   qualitative research - chapter 2 - ethnography
Silverman qualitative research - chapter 2 - ethnography
 
Sihanoukville
Sihanoukville Sihanoukville
Sihanoukville
 
2016 Social Media Best Practices for ITB
2016 Social Media Best Practices for ITB2016 Social Media Best Practices for ITB
2016 Social Media Best Practices for ITB
 
Resum bab 1 2
Resum bab  1 2Resum bab  1 2
Resum bab 1 2
 
Músculos del pie, fascia y aponeurosis plantar
Músculos del pie, fascia y aponeurosis plantarMúsculos del pie, fascia y aponeurosis plantar
Músculos del pie, fascia y aponeurosis plantar
 
The 12 soil orders
The 12 soil ordersThe 12 soil orders
The 12 soil orders
 
Pilpilén
PilpilénPilpilén
Pilpilén
 
Newer Oral Anticoagulants or warfarin in DVT/PE
Newer Oral Anticoagulants or warfarin in DVT/PENewer Oral Anticoagulants or warfarin in DVT/PE
Newer Oral Anticoagulants or warfarin in DVT/PE
 

Similar to Vte in pregnancy (written)

Vaginal bleeding du ing pregnancy (2)
Vaginal bleeding du ing pregnancy (2)Vaginal bleeding du ing pregnancy (2)
Vaginal bleeding du ing pregnancy (2)bsnguyenhongchau
 
Vaginal bleeding du ing pregnancy (1)
Vaginal bleeding du ing pregnancy (1)Vaginal bleeding du ing pregnancy (1)
Vaginal bleeding du ing pregnancy (1)bsnguyenhongchau
 
Pregnancy and heart diseases PPT.pptx
Pregnancy and heart diseases PPT.pptxPregnancy and heart diseases PPT.pptx
Pregnancy and heart diseases PPT.pptxAbhishek Sakwariya
 
Anaesthetic management of obstetric emergencies
Anaesthetic management of obstetric emergenciesAnaesthetic management of obstetric emergencies
Anaesthetic management of obstetric emergenciesWahid altaf Sheeba hakak
 
Anaesthetic management of obstetric emergencies
Anaesthetic management of obstetric emergenciesAnaesthetic management of obstetric emergencies
Anaesthetic management of obstetric emergenciesWahid altaf Sheeba hakak
 
Venous Thromboembolism in Obstetrics
Venous Thromboembolism in ObstetricsVenous Thromboembolism in Obstetrics
Venous Thromboembolism in Obstetricslimgengyan
 
Vte risk assessment program presentation 2.ppt
Vte risk assessment program presentation 2.pptVte risk assessment program presentation 2.ppt
Vte risk assessment program presentation 2.pptlimgengyan
 
Pregnancy Management Guidelines in Women with Cardiac Diseases.ppt
Pregnancy Management Guidelines in Women with Cardiac Diseases.pptPregnancy Management Guidelines in Women with Cardiac Diseases.ppt
Pregnancy Management Guidelines in Women with Cardiac Diseases.pptIreenPahang
 
Deep vein thrombosis and pulmonary embolism in pregnancy
Deep vein thrombosis and pulmonary embolism in pregnancyDeep vein thrombosis and pulmonary embolism in pregnancy
Deep vein thrombosis and pulmonary embolism in pregnancyKahtan Ali
 
Use of antithrombotic agents during pregnancy
Use of antithrombotic agents during pregnancyUse of antithrombotic agents during pregnancy
Use of antithrombotic agents during pregnancygisa_legal
 
Investigation of suspected pulmonary embolism in pregnancy
Investigation of suspected pulmonary embolism in pregnancyInvestigation of suspected pulmonary embolism in pregnancy
Investigation of suspected pulmonary embolism in pregnancySCGH ED CME
 
Articulo medico hemorragia postparto
Articulo medico hemorragia postpartoArticulo medico hemorragia postparto
Articulo medico hemorragia postpartochino72
 
Pregnancy and Heart Disease
Pregnancy and Heart DiseasePregnancy and Heart Disease
Pregnancy and Heart DiseaseNizam Uddin
 
Pregnant heart 111
Pregnant heart 111Pregnant heart 111
Pregnant heart 111Nizam Uddin
 
APH(Antepartum Hemorrhage)& PPH(Postpartum hemorrhage).pptx
APH(Antepartum Hemorrhage)& PPH(Postpartum hemorrhage).pptxAPH(Antepartum Hemorrhage)& PPH(Postpartum hemorrhage).pptx
APH(Antepartum Hemorrhage)& PPH(Postpartum hemorrhage).pptxHafsaRazzaq6
 

Similar to Vte in pregnancy (written) (20)

Vaginal bleeding du ing pregnancy (2)
Vaginal bleeding du ing pregnancy (2)Vaginal bleeding du ing pregnancy (2)
Vaginal bleeding du ing pregnancy (2)
 
Vaginal bleeding du ing pregnancy (1)
Vaginal bleeding du ing pregnancy (1)Vaginal bleeding du ing pregnancy (1)
Vaginal bleeding du ing pregnancy (1)
 
Pregnancy and heart diseases PPT.pptx
Pregnancy and heart diseases PPT.pptxPregnancy and heart diseases PPT.pptx
Pregnancy and heart diseases PPT.pptx
 
L27 Venous thromboembolism
L27 Venous thromboembolismL27 Venous thromboembolism
L27 Venous thromboembolism
 
Anaesthetic management of obstetric emergencies
Anaesthetic management of obstetric emergenciesAnaesthetic management of obstetric emergencies
Anaesthetic management of obstetric emergencies
 
Anaesthetic management of obstetric emergencies
Anaesthetic management of obstetric emergenciesAnaesthetic management of obstetric emergencies
Anaesthetic management of obstetric emergencies
 
Venous Thromboembolism in Obstetrics
Venous Thromboembolism in ObstetricsVenous Thromboembolism in Obstetrics
Venous Thromboembolism in Obstetrics
 
G tt d up to date (1)
G tt d up to date (1)G tt d up to date (1)
G tt d up to date (1)
 
Vte risk assessment program presentation 2.ppt
Vte risk assessment program presentation 2.pptVte risk assessment program presentation 2.ppt
Vte risk assessment program presentation 2.ppt
 
APH.pptx
APH.pptxAPH.pptx
APH.pptx
 
Pregnancy Management Guidelines in Women with Cardiac Diseases.ppt
Pregnancy Management Guidelines in Women with Cardiac Diseases.pptPregnancy Management Guidelines in Women with Cardiac Diseases.ppt
Pregnancy Management Guidelines in Women with Cardiac Diseases.ppt
 
Deep vein thrombosis and pulmonary embolism in pregnancy
Deep vein thrombosis and pulmonary embolism in pregnancyDeep vein thrombosis and pulmonary embolism in pregnancy
Deep vein thrombosis and pulmonary embolism in pregnancy
 
Use of antithrombotic agents during pregnancy
Use of antithrombotic agents during pregnancyUse of antithrombotic agents during pregnancy
Use of antithrombotic agents during pregnancy
 
Investigation of suspected pulmonary embolism in pregnancy
Investigation of suspected pulmonary embolism in pregnancyInvestigation of suspected pulmonary embolism in pregnancy
Investigation of suspected pulmonary embolism in pregnancy
 
Articulo medico hemorragia postparto
Articulo medico hemorragia postpartoArticulo medico hemorragia postparto
Articulo medico hemorragia postparto
 
Coma in pregnancy
Coma in pregnancyComa in pregnancy
Coma in pregnancy
 
Pregnancy and Heart Disease
Pregnancy and Heart DiseasePregnancy and Heart Disease
Pregnancy and Heart Disease
 
Pregnant heart 111
Pregnant heart 111Pregnant heart 111
Pregnant heart 111
 
Siddiqui2009
Siddiqui2009Siddiqui2009
Siddiqui2009
 
APH(Antepartum Hemorrhage)& PPH(Postpartum hemorrhage).pptx
APH(Antepartum Hemorrhage)& PPH(Postpartum hemorrhage).pptxAPH(Antepartum Hemorrhage)& PPH(Postpartum hemorrhage).pptx
APH(Antepartum Hemorrhage)& PPH(Postpartum hemorrhage).pptx
 

More from Siti Nurul Afiqah Johari (11)

Benign Skin Tumor
Benign Skin TumorBenign Skin Tumor
Benign Skin Tumor
 
Rheumatological Emergencies
Rheumatological EmergenciesRheumatological Emergencies
Rheumatological Emergencies
 
Diagnosis of Acute Pancreatitis
Diagnosis of Acute PancreatitisDiagnosis of Acute Pancreatitis
Diagnosis of Acute Pancreatitis
 
Chest emergencies
Chest emergenciesChest emergencies
Chest emergencies
 
Anemia in elderly
Anemia in elderlyAnemia in elderly
Anemia in elderly
 
Male Hypogonadism
Male HypogonadismMale Hypogonadism
Male Hypogonadism
 
Otc drugs
Otc drugsOtc drugs
Otc drugs
 
Itp
ItpItp
Itp
 
Atopic derma
Atopic dermaAtopic derma
Atopic derma
 
Turner syndrome
Turner syndromeTurner syndrome
Turner syndrome
 
Treatment of refractory ascites
Treatment of refractory ascitesTreatment of refractory ascites
Treatment of refractory ascites
 

Recently uploaded

Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 

Recently uploaded (20)

Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 

Vte in pregnancy (written)

  • 1. Name: Siti Nurul Afiqah binti Johari ID No.: 10-6-95 VENOUS THROMBOEMBOLISM IN PREGNANCY Women are at an increased risk of both venous and arterial thromboembolism during pregnancy. Compared to women who are not pregnant, the risk of arterial thromboembolism (strokes and heart attacks) is increased 3- to 4-fold and the risk of venous thromboembolism (VTE) is increased 4- to 5-fold. Postpartum, the risk is even higher (20-fold). The overall prevalence of thromboembolic events during pregnancy is approximately 2 per 1000 deliveries. Approximately 20% of these events are arterial, and the other 80% are venous. VTE accounts for 1.1 deaths per 100 000 deliveries, or 10% of all maternal deaths. Approximately 80% of venous thromboembolic events during pregnancy are deep vein thrombosis (DVT) and 20% are pulmonary emboli. Approximately one third of pregnancy- related DVT and half of pregnancy-related pulmonary emboli occur after delivery. When DVT occurs during pregnancy, it is more likely to be proximal, massive,and in the left lower extremity. Distal thrombosis are as likely to occur on the right as on the left, but proximal thrombosis occurring under the influence of estrogen are more likely to be on the left. This left-sided predominance is thought to be attributable to a relative stenosis of the left common iliac vein where it lies between the lumbar vertebral body and the right common iliac artery, but the true mechanism is unknown. Pelvic vein thrombosis, which account for less than 1% of all cases of DVT, are rare outside of pregnancy or pelvic surgery yet account for approximately 10% of DVT during pregnancy and the postpartum period. Pregnant women are probably at an increased risk for VTE as a result of hormonally induced decreased venous capacitance and decreased venous outflow, possibly as a result of mechanical obstruction by the uterus, and questionably as a result of decreased mobility. These factors, along with vascular injury, are important, especially during the postpartum period, but the risk of VTE is as high during the first trimester as it is during the second and third trimesters. Therefore, the risk of VTE increases before many of the anatomic changes of pregnancy take place, suggesting that; overall, the most important reason for the increased risk of VTE during pregnancy is hypercoagulability. Normal pregnancy is accompanied by increased concentrations of factors VII, VIII, X, and von Willebrand factor and by pronounced increases in fibrinogen. Factors II, V, and IX are relatively unchanged. Free protein S, the active, unbound form, is decreased during pregnancy secondary to increased levels of its binding protein, the complement component C4b. Plasminogen activator inhibitor type 1 (PAI-1) levels increase 5-fold. Levels of PAI-2, produced by the placenta, increase dramatically during the third trimester. Markers of thrombin generation such as prothrombin F1+2 and thrombin-antithrombin (TAT) complexes are increased. These changes, which may not completely return to baseline until more than 8 weeks postpartum, begin with conception. So does the risk of thrombosis. The hypercoagulability of pregnancy has likely evolved to protect women from hemorrhage at the time of miscarriage or childbirth. Indeed, in the developing world, the leading cause of maternal death is still hemorrhage, but in Western Europe and the United States, where hemorrhage is successfully treated or prevented, the leading cause of maternal death is thromboembolic disease.
  • 2. Risk Factors for Thrombosis in Pregnancy There are a number of known risk factors, some hereditary and others acquired. In 80% of patients, at least one risk factor can be identified. Notably, the antenatalperiod is known to be a weak risk factor and the postpartum period a moderate risk factor. Often more than one risk factor is present and these should be actively identified when assessing the patient for VTE during and post-pregnancy. Inherited factors  Factor V Leiden mutation (most common).  Prothrombin gene G20210A mutation.  Antithrombin III deficiency.  Protein C deficiency.  Protein S deficiency.  Hyperhomocysteinaemia.  Dysfibrinogenaemia.  Disorders of plasminogen and plasminogen activation.  Strong family history. Acquired factors  Obesity - body mass index (BMI) ≥30 kg/m2 .  Immobilization (>4 days of bed rest).  Previous thrombotic event.  Smoking.  Trauma.  Inflammatory disorders such as inflammatory bowel disease.  Cancer.  Estrogen therapy (including contraception and hormone replacement therapy).  Sepsis, including urinary tract infections.  Gross varicose veins.  Antiphospholipid syndrome.  Nephrotic syndrome.  Paroxysmal nocturnal haemoglobinuria.  Cerebrovascular event.  Polycythaemia vera.  Sickle cell disease.  Lupus.  Anemia.  Diabetes.  Hypertension.  Long-haul travel of ≥4 hours. Factors specific to pregnancy and delivery complications  Venous stasis.  Maternal age of ≥35 years.  Multiparity.  Gestation <36 weeks.  Instrument-assisted or caesarean delivery.  Haemorrhage (antepartum and postpartum)  Pre-eclampsia.
  • 3.  Prolonged labour.  Hyperemesis.  Postpartum infection. Clinical Presentation Presentation is similar to non-pregnant patients with DVT or PE.  DVT: leg pain and discomfort (the left is more commonly affected), swelling, tenderness, edema, increased temperature and a raised white cell count. There may also be abdominal pain. The difficulty is that some of these symptoms may be found in normal pregnancies. The patient may also be asymptomatic with a retrospective diagnosis being made following a PE.  PE: dyspnea, pleuritic chest pain, hemoptysis, faintness, collapse. The patient may have focal signs in the chest, tachypnea, a raised jugular venous pressure (JVP) and there may be ECG changes (S1Q3T3). Arterial blood gases with the patient sitting down may show respiratory alkalosis and hypoxemia. There may also be symptoms or signs of a DVT. Differential Diagnosis  DVT: swelling and lower leg discomfort are not unusual in a normal pregnancy. Other possibilities include muscle strain, a ruptured Baker’s cyst, cellulitis, superficial thrombophlebitis, ruptured plantaris tendon and trauma.  PE: potentially extensive but specifically rule out chest infection and an intra- abdominal bleed (look for abdominal signs, shoulder tip pain from diaphragmatic irritation and a low JVP). Diagnostic Approach of VTE The two most common initial symptoms, present in more than 80% of women with pregnancy-related DVT, are pain and swelling in an extremity. When signs or symptoms suggest new onset DVT, the recommended initial diagnostic test is compression ultrasonography of the proximal veins. When results are equivocal or an iliac vein thrombosis is suspected, magnetic resonance venography (MRV) may be used.
  • 4. The diagnosis of new onset pulmonary embolism (PE) is similar to that in the non-pregnant individual. Ventilation/perfusion (V/Q) scanning gives relatively low radiation exposure to the fetus. With an indeterminate study in a woman without a DVT, a confirmatory test, such as angiography or spiral computed tomography (spiral CT), is necessary to prevent the woman from unnecessary exposure to anticoagulation during the rest of her pregnancy, at delivery, or in future pregnancies.
  • 5. Management of VTE Massive life-threatening PE:  Collapsed, shocked patients need to be managed by an experienced multidisciplinary team involving senior obstetricians, physicians and radiologists.  An urgent portable echocardiogram or CTPA within one hour of presentation should be arranged.  If massive PE is confirmed or, in extreme circumstances prior to confirmation, immediate thrombolysis should be considered.  Intravenous unfractionated heparin is the preferred treatment. General points  In a woman with a past history of VTE or with a known inherited thrombophilia, it is best to refer her prior to a planned pregnancy for optimum prophylaxis throughout the pregnancy. Refer all women who are on warfarin, as this will have to be stopped or replaced by heparin before the seventh week of conception, depending on her risk of VTE.  Medical anticoagulation is the treatment of choice for acute VTE. Subsequently, surgical interventions may be considered: patients suffering from recurrent PEs despite adequate anticoagulation (or where there is an absolute contra-indication to anticoagulation) may benefit from placement of a temporary caval filter and, in those cases where there is limb or life-threatening embolus, a surgical embolectomy or thrombus fragmentation may be attempted.  Anticoagulation is by far the most common treatment option. Heparin is the most frequently used drug, being non-toxic to the fetus (it does not cross the placental barrier). However, its main disadvantages are that it has to be parentally administered and, in the long-term, may give rise to heparin-induced osteoporosis and thrombocytopenia. In some patients, it can also provoke a painful, localized allergic reaction on administration. Warfarin is the other treatment option in the postnatal patient but it must be avoided antenatally, as it is teratogenic and can also cause placental abruption and fetal/neonatal hemorrhage.  In clinically suspected DVT or PE, treatment with unfractionated heparin or LMWH should be given until the diagnosis is excluded by objective testing, unless treatment is strongly contraindicated. Initiating treatment There are severaldifferent types of heparin to choose from:  LMWH: this is the drug of choice. It has been shown to be more effective than unfractionated heparin with lower mortality and fewer hemorrhagic complications in the initial treatment of DVT in non-pregnant subjects. LMWHs are as effective as unfractionated heparin for treatment of PE. The exact dose will depend on the manufacturer's recommendations but this is based on the patient's early pregnancy weight and should be administered subcutaneously twice daily. There should be clear local guidelines for the dosage of LMWH to be used.  Intravenous unfractionated heparin: this is an extensively used drug in the acute management of VTE, particularly massive PE with cardiovascular compromise. It is initiated with a loading dose of 5,000 international units (IU) followed by a continuous infusion of 1,000-2,000 IU/hour depending on activated partial thromboplastin time (aPTT) measurements (daily - at least), the first of which is taken six hours after the loading dose. Thus, there is the benefit of accurate drug
  • 6. administration but it has been demonstrated that there are a number of difficulties with accurate aPTT measurement (when the sample is taken and in the laboratory), particularly late in pregnancy when interpretation of the results can be problematic. Prolonged use in pregnancy may give rise to the problems described above.  Subcutaneous unfractionated heparin: this has been shown to be as effective as the intravenous form. It is administered as a 5,000 IU bolus and subsequent 15,000- 20,000 IU doses at 12-hourly intervals. The aPTT needs to be checked and is best done midway between the 12-hourly doses, once every 24 hours. A target of 1.5-2.5 times the control should be aimed for. Additionally, the leg should be elevated and a graduated elastic compression stocking applied to reduce oedema. Mobilisation with graduated elastic compression stockings should be encouraged. Maintenance therapy Pregnancy Heparins are the maintenance treatment of choice. Dose-adjusted subcutaneous, unfractionated heparin or subcutaneous LMWH are effective alternatives to oral anticoagulants in maintenance treatment of VTE.  Subcutaneous LMWH appears to have advantages over aPTT-monitored unfractionated heparin in the maintenance treatment of VTE in pregnancy. The simplified therapeutic regimen for LMWH tends to be more convenient for patients, minimising blood tests (routine platelet counts are not required and levels of anti-Xa will only need to be monitored where there are extremes of weight: <50 kg or >90 kg) and allowing outpatient treatment. Women should be taught to self-inject and can then be managed as outpatients until delivery.  If unfractionated heparin is used, monitor the platelet count at least every other day for the first 14 days or until treatment is stopped (whichever comes first). Seek specialist advice if the patient develops heparin-induced thrombocytopenia or a heparin allergy and requires continuing anticoagulant therapy. She should be managed with the heparinoid, danaparoid sodium or fondaparinux, under specialist supervision. Labour When the patient thinks she is going into labour, she should stop injecting and get in touch with the delivery ward staff that will manage the anticoagulation throughout labour and immediately post-delivery. Alternatively, planned elective induction of labour or caesarean section at least 12 hours after prophylactic-dose LMWH or 24 hours after therapeutic-dose LMWH can be considered. As these patients are at high risk of hemorrhage, they will be managed with intravenous unfractionated heparin throughout this time. Regional anaesthetic or analgesic techniques should not be undertaken until at least 24 hours after the last dose of therapeutic LMWH. Postpartum Depending on the patient's individual circumstances, she may be managed with ongoing heparin treatment or warfarin postpartum. If she opts for warfarin, this needs to be avoided until at least day three postpartum with an INR check at day two of warfarin treatment: aim for an INR between 2 and 3. Continue heparin treatment until there have been two successive readings of an INR >2. Although these drugs are detectable in breast milk, all are safe for use during breast-feeding because warfarin metabolites are inactive and heparin is not absorbed through the gastrointestinal tract.
  • 7. Postnatal review for women who develop VTE during pregnancy or the puerperium should, whenever possible, be at an obstetric medicine clinic or a joint obstetric hematology clinic. Stopping treatment In theory, therapy should be continued for six months as would be the case for non-pregnant patients. However, the postpartum state is a period of physiological fluctuation of coagulation factors. Therefore, current advice is to continue therapy for at least 6-12 weeks postpartum or until at least three months of therapy have been completed. At that point, the patient should be assessed for the presence of ongoing risk factors for a VTE prior to making the decision to stop anticoagulation therapy. Complications Thrombophilia and placental vascular complications  Fetal loss: although the figures are likely to be small (there are not many studies), there is thought to be a doubling of risk of fetal loss in women with genetic thrombophilia.  Intrauterine growth restriction: a specific association between this and thrombophilia has not been identified but chronic abruption and extensive placental infraction have been noted to occur more frequently in these patients.  HELLP syndrome: Hemolysis, Elevated Liver enzymes, Low Platelet count - this may be associated with certain forms of thrombophilia. Post-thrombotic syndrome Up to 60% of patients who have experienced a DVT go on to have post-thrombotic syndrome up to 12 months following the acute event. This arises from damage to the lumen of the vein following the presence of a thrombus. Subsequently, patients manifest symptoms and signs akin to those of varicose veins: aching, swollen legs, pruritus, dermatitis and hyperpigmentation of the affected area. Ulceration and cellulitis may complicate the picture. Compression stockings worn on the affected leg for at least two years have been recommended after the acute event to reduce the risk of developing post-thrombotic syndrome. However, a recent large randomized trial found no evidence to support this. PE is the other complication of DVTs and is discussed above. Other complications Prolonged unfractionated heparin use during pregnancy may result in osteoporosis and fractures. Prevention: prophylaxis Guidance from the Royal College of Obstetricians and Gynecologists’ suggests: Antenatally  Regardless of their VTE risk, dehydration and immobilization of the patient should be avoided throughout pregnancy.  Women at high risk of VTE in pregnancy should be offered pre-pregnancy counseling and a prospective management plan for thromboprophylaxis in pregnancy.
  • 8. Those who become pregnant before receiving such counseling should be referred to a nominated expert early in pregnancy.  All women with previous VTE should receive postpartum prophylaxis, as this is the time of highest risk.  In addition, women whose original VTE was unprovoked, idiopathic or related to estrogen, or who have other risk factors, a family history of VTE in a first- degree relative or a documented thrombophilia require LMWH antenatally and for six weeks postpartum.  Women with recurrent VTE may already be on warfarin. They should be advised to stop warfarin and change to LMWH as soon as pregnancy is confirmed, ideally within two weeks of the missed period and before the sixth week of pregnancy. Women not on warfarin should be advised to start LMWH as soon as they have a positive pregnancy test.  Women with asymptomatic inherited or acquired thrombophilia only, may be managed with close surveillance antenatally and be considered for LMWH for at least seven days postpartum. Exceptions are women with antithrombin deficiency, those with more than one thrombophilic defect (including homozygosity for factor V Leiden) or those with additional risk factors where antenatal prophylaxis should be considered. Intrapartum Women taking LMWH should be advised that, if they bleed vaginally or contractions begin, they should not inject any further doses. They should be assessed in hospital and further doses be prescribed by medical staff. Postpartum  All women with obesity (BMI greater than 40 kg/m2 ) should be considered for prophylactic LMWH for seven days after delivery. Other postnatal risks include prolonged labour, immobility, infection, hemorrhage and blood transfusion.  All women who have had an emergency Caesarean section should be considered for LMWH for seven days after delivery. All women who have had an elective caesarean section who have one or more additional risk factors should be considered for LMWH for seven days after delivery. In addition, properly applied graduated compression stockings are recommended for women travelling long-distance for more than four hours, women who are still outpatients but have prior VTE (usually combined with LMWH), women who are hospitalized and have a contra- indication to LMWH and those who are hospitalized post-caesarean section (combined with LMWH) and considered to be at particularly high risk of VTE. References: 1. http://www.aafp.org/afp/2008/0615/p1709.html 2. http://atvb.ahajournals.org/content/29/3/326.full 3. http://patient.info/doctor/venous-thromboembolism-in-pregnancy#ref-3